| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |